Who is sponsoring RETRO-ROC?

RETRO-ROC is sponsored by Grupo Español de Investigación en Cáncer de Ovario.

What condition does RETRO-ROC study?

RETRO-ROC studies Ovarian Epithelial Cancer Recurrent.

What drugs are being tested in RETRO-ROC?

Interventions: Trabectedin and Pegylated Liposomal Doxorubicin.

What is the status of RETRO-ROC?

RETRO-ROC is currently COMPLETED.

Last reviewed 2020-03-26 · How we verify

Multicenter and Retrospective Observational Study to Analyze the Efficacy and Safety of the Combination With Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to Data Sheet (RETRO-ROC)

NCT02394015 COMPLETED

Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC.

Details

Lead sponsor	Grupo Español de Investigación en Cáncer de Ovario
Status	COMPLETED
Enrolment	90
Start date	2013-05-06
Completion	2017-12

Conditions

Ovarian Epithelial Cancer Recurrent

Interventions

Trabectedin and Pegylated Liposomal Doxorubicin

Primary outcomes

Efficacy progression-free survival (PFS) — Up to 12 months
Describe the impact of trabectedin - pegylated liposomal doxorubicin combination of retreatment with platinum ROC, in terms of progression-free survival ( PFS).
Overall survival (OS) — Up to 12 months
Describe the impact of trabectedin - pegylated liposomal doxorubicin combination of retreatment with platinum ROC, in terms of overall survival (OS ) .